There are many funding opportunities that support the conduct of rigorous, cutting-edge dissemination and implementation research at the National Cancer Institute (NCI) and across the National Institutes of Health (NIH). The most prominent funding opportunity is the Trans-NIH program announcement with special receipt, referral and/or review (PAR), Dissemination and Implementation Research in Health (DIRH). NCI, along with many other participating institutes and centers across NIH, issued this PAR for R01, R21, and/or R03 funding sources. Learn more about this implementation science (IS) funding opportunity and find resources for prospective IS applicants.
Trans-NIH PAR, Dissemination and Implementation Research in Health
R01, Dissemination and Implementation Research in Health (PAR-22-105, Clinical Trial Optional)
This funding opportunity provides research project grants to support discrete, specified research projects led by an investigator in a topic area representing his or her specific interests and competencies. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Applications may not exceed 5 years.
R03, Dissemination and Implementation Research in Health (PAR-22-106, Clinical Trial Not Allowed)
This funding opportunity provides small research grants to support the initiation of studies that are generally for preliminary short-term projects. Applicants for an R03 award may request a project period of up to 2 years and a budget for direct costs of up to $50,000 per year. While the grant is nonrenewable, there is less competition for these start-up research project funds.
R21, Dissemination and Implementation Research in Health (PAR-22-109, Clinical Trial Optional)
This funding opportunity provides grants that are intended to encourage exploratory or developmental research projects by supporting the development of pilot projects or feasibility studies to support creative, novel, and high-risk/high-payoff research. Applicants may request a project period of up to 2 years and the combined budget for direct costs may not exceed $275,000.
Clinical Trials & Implementation Science
NIH Clinical Trial Policies
In 2016, NIH launched a multi-faceted effort to enhance its stewardship over clinical trials. The goal of this effort is to encourage advances in the design, conduct, and oversight of clinical trials while elevating the entire biomedical research enterprise to a new level of transparency and accountability. The NIH definition of a clinical trial was revised in 2014 in anticipation of these stewardship reforms to ensure a clear and responsive definition of a clinical trial. If you need assistance determining whether your proposed study is a clinical trial, visit the NIH Office of Extramural Research clinical trial website.
What is a Clinical Trial?
The NIH definition of a clinical trial is a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
Clinical Trial-Specific Funding Opportunities
NIH requires that all applications involving one or more clinical trials be submitted through a Notice of Funding Opportunity (NOFO) specifically designed for clinical trials. The purpose of this policy is to improve our ability to identify proposed clinical trials, ensure that key pieces of trial-specific information are submitted with each application, and uniformly apply trial-specific review criteria. NOFOs are classified as Clinical Trial Optional, Clinical Trial Required, or Clinical Trial Not Allowed.
More Prospective Grantee Resources
Learn about NCI’s participation in the set of NIH announcements, “Dissemination and Implementation Research in Health (R01/R21 - Clinical Trial Optional, R03 – Clinical Trial Not Allowed).Webinar
The Science of Implementation in Health and Healthcare (SIHH) Study Section reviews applications that identify, develop, and evaluate dissemination and implementation theories, strategies and methods designed to integrate evidence-based health interventions into public health, clinical, and community settings. Applications reviewed in SIHH should have a major methods, strategy, or theoretical development component in implementation science in order to understand how interventions are implemented and measure implementation outcomes in public health, clinical, and community settings.Membership and Meeting Rosters
In 2015, IS team members published a portfolio analysis of dissemination and implementation grants funded by the NCI in cancer prevention and control between 2000 to 2012. The portfolio analysis identified 67 NCI grant awards with an implementation science focus. The R01 mechanism was the most common funding mechanism. Prevention grants were most common (49.3%) and cancer treatment grants were least (4.5%), with most grants including both quantitative and qualitative methods (69%).Open-Access Article
Current and previous grants funded through the DIRH NOFO in cancer prevention and control by DCCPS are listed in a searchable table for reference.Funded Grants
NCI’s DCCPS Funding Opportunities
Explore current funding opportunities, as well as information about NIH’s budget process, grant funding strategies and policies, and more.